Trial Profile
A Multi-Center, Randomized, Double-Masked Parallel Group Study Evaluating the Efficacy, Safety, and QOL of R89674 0.25% Ophthalmic Solution Compared to Vehicle or an Active Control in a Modified Model of Environmental Seasonal Allergic Conjunctivitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Jun 2014
Price :
$35
*
At a glance
- Drugs Alcaftadine (Primary)
- Indications Allergic conjunctivitis
- Focus Registrational; Therapeutic Use
- Sponsors Vistakon Pharmaceuticals
- 24 Jun 2014 New trial record